Investor Presentaiton

INVESTMENT THESIS STRONG PRODUCT PORTFOLIO ROBUST SAFETY AND CLINICAL DATA FOCUSED COMMERCIAL MODEL • • • · · Comprehensive portfolio of 5th generation silicone gel breast implants Strong tissue expander portfolio with health and economic benefits Safety profile supported by robust 10-year data¹ Backed by leading Platinum20TM warranty program Uniquely focused on breast aesthetics and the plastic surgery channel Expanded sales and marketing efforts dedicated to driving patients to plastic surgery customers • Focused on continuing to expand hospital account base through 2021 IMMEDIATE TAM GROWTH OPPORTUNITY2 MULTIPLE TAM EXPANSION OPPORTUNITIES · • $600 million immediately addressable TAM (US Augmentation and Reconstruction + Japan) Large growth drivers through deeper and broader account penetration • Significant OUS market opportunity (Canada approval anticipated in 2021) Product innovation and development to drive new growth • CLEAR PATH TO PROFITABILITY • Exited 10'21 with strong momentum of 47% YoY growth for Breast Products segment Organizational structure optimized to increase operating leverage • Divested mira Dry business to 1315 Capital 1 Stevens WG, Calobrace MB, Alizadeh A, Zeidler KR, Harrington JL, d'Incelli RC. Ten-year core study data for Sientra's Food and Drug Administration - approved round and shaped breast implants with cohesive silicone gel. Plast Reconstr Surg. 2018;141(4S):7S-19S; sientra. 2 Market size based on company estimates and American Society of Plastic Surgeons annual statics report (2019) 5

View entire presentation